Ireland - English - HPRA (Health Products Regulatory Authority)

ltt pharma limited - propranolol hydrochloride - prolonged release capsules - 160 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

ips healthcare limited - propranolol hydrochloride - prolonged release capsules - 160 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing - propranolol hydrochloride - prolonged release capsules - 160

Ireland - English - HPRA (Health Products Regulatory Authority)

ltt pharma limited - propranolol hydrochloride - prolonged release capsules - 160 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

astrazeneca uk limited - propranolol hydrochloride - prolonged release capsules - 160 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

ips healthcare limited - propranolol hydrochloride - prolonged release capsules - 160 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing - propranolol hydrochloride - prolonged release capsules - 160

Canada - English - Health Canada

wyeth-ayerst canada inc. - propranolol hydrochloride - liquid - 1mg - propranolol hydrochloride 1mg - beta-adrenergic blocking agents

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluvoxamine maleate -

United States - English - NLM (National Library of Medicine)

cipla usa inc. - rizatriptan benzoate (unii: wr978s7qhh) (rizatriptan - unii:51086hbw8g) - rizatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. limitations of use   - rizatriptan benzoate tablets should only be used where a clear diagnosis of migraine has been established. if a patient has no response for the first migraine attack treated with rizatriptan benzoate, the diagnosis of migraine should be reconsidered before rizatriptan benzoate is administered to treat any subsequent attacks. - rizatriptan benzoate tablets is not indicated for use in the management of hemiplegic or basilar migraine [see contraindications (4)] - rizatriptan benzoate tablets is not indicated for the prevention of migraine attacks. - safety and effectiveness of rizatriptan benzoate tablets have not been established for cluster headache. rizatriptan benzoate tablets is contraindicated in patients with: - ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or